Apr 30 |
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
|
Apr 5 |
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
Apr 3 |
ARS Pharmaceuticals responded to FDA CRL for epinephrine nasal spray
|
Apr 3 |
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
|
Apr 3 |
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
|
Apr 1 |
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
|
Mar 28 |
Top 5 Health Care Stocks That May Plunge In March
|
Mar 26 |
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
|
Mar 21 |
ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results
|
Mar 21 |
ARS Pharmaceuticals reports Q4 results
|